These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30930164)

  • 21. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.
    Huang Y; Liu W; Zhao C; Shi X; Zhao Q; Jia J; Wang A
    Eur J Med Chem; 2024 Sep; 275():116547. PubMed ID: 38852339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs.
    Johnson K; Liu L; Majdzadeh N; Chavez C; Chin PC; Morrison B; Wang L; Park J; Chugh P; Chen HM; D'Mello SR
    J Neurochem; 2005 May; 93(3):538-48. PubMed ID: 15836613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical proteomics and functional proteomics strategies for protein kinase inhibitor validation and protein kinase substrate identification: applications to protein kinase CK2.
    Gyenis L; Turowec JP; Bretner M; Litchfield DW
    Biochim Biophys Acta; 2013 Jul; 1834(7):1352-8. PubMed ID: 23416530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylation of cyclin Y by CDK14 induces its ubiquitination and degradation.
    Li S; Song W; Jiang M; Zeng L; Zhu X; Chen J
    FEBS Lett; 2014 May; 588(11):1989-96. PubMed ID: 24794231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents.
    Marak BN; Dowarah J; Khiangte L; Singh VP
    Eur J Med Chem; 2020 Oct; 203():112571. PubMed ID: 32707525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
    Pearson RJ; Blake DG; Mezna M; Fischer PM; Westwood NJ; McInnes C
    Cell Chem Biol; 2018 Sep; 25(9):1107-1116.e4. PubMed ID: 30017915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-455 inhibits breast cancer cell proliferation through targeting CDK14.
    Wang B; Zou A; Ma L; Chen X; Wang L; Zeng X; Tan T
    Eur J Pharmacol; 2017 Jul; 807():138-143. PubMed ID: 28300591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diarylureas and Diarylamides with Oxazolo[5,4-d]pyrimidine Scaffold as Angiogenesis Inhibitors.
    Deng YH; Liu JP; Cheng YJ; Liu Y; Sun LP
    Chem Biodivers; 2016 Sep; 13(9):1230-1239. PubMed ID: 27448711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
    Kalra S; Joshi G; Munshi A; Kumar R
    Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.
    Yan B; Liu L; Huang S; Ren Y; Wang H; Yao Z; Li L; Chen S; Wang X; Zhang Z
    Chem Commun (Camb); 2017 Mar; 53(26):3637-3640. PubMed ID: 28267172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis, and Evaluation of the Kinase Inhibition Potential of Pyridylpyrimidinylaminophenyl Derivatives.
    Manchanda P; Parshad B; Kumar A; Tiwari RK; Shirazi AN; Parang K; Sharma SK
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28317151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Cysteinome of Protein Kinases as a Target in Drug Development.
    Chaikuad A; Koch P; Laufer SA; Knapp S
    Angew Chem Int Ed Engl; 2018 Apr; 57(16):4372-4385. PubMed ID: 28994500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Chemoproteomic Strategy for Direct and Proteome-Wide Covalent Inhibitor Target-Site Identification.
    Browne CM; Jiang B; Ficarro SB; Doctor ZM; Johnson JL; Card JD; Sivakumaren SC; Alexander WM; Yaron TM; Murphy CJ; Kwiatkowski NP; Zhang T; Cantley LC; Gray NS; Marto JA
    J Am Chem Soc; 2019 Jan; 141(1):191-203. PubMed ID: 30518210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?
    Wesierska-Gadek J; Krystof V
    Ann N Y Acad Sci; 2009 Aug; 1171():228-41. PubMed ID: 19723060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
    Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
    Darwish SS; Abdel-Halim M; Salah M; Abadi AH; Becker W; Engel M
    Eur J Med Chem; 2018 Sep; 157():1031-1050. PubMed ID: 30193214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors.
    Feng Y; Yin Y; Weiser A; Griffin E; Cameron MD; Lin L; Ruiz C; Schürer SC; Inoue T; Rao PV; Schröter T; Lograsso P
    J Med Chem; 2008 Nov; 51(21):6642-5. PubMed ID: 18834107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.